Knockdown of NF-E2-related factor 2 inhibits the proliferation and growth of U251MG human glioma cells in a mouse xenograft model

Oncology Reports

Volumn 30, Issue 1, 2013, Pages 157-164

  Ji, Xiang Jun ^a   Chen, Sui Hua ^a   Zhu, Lin ^a   Pan, Hao ^a   Zhou, Yuan ^a   Li, Wei ^a   You, Wan Chun ^a   Gao, Chao Chao ^a   Zhu, Jian Hong ^a   Jiang, Kuan ^a   Wang, Han Dong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Caspase 3; CD31; Glioblastoma multiforme; Ki 67; NF E2 related factor 2; Proliferation

Indexed keywords

CASPASE 3; CD31 ANTIGEN; KI 67 ANTIGEN; SILICON; TRANSCRIPTION FACTOR NRF2;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CAPILLARY DENSITY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MODEL; TUMOR XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD31; APOPTOSIS; BRAIN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HUMANS; KI-67 ANTIGEN; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NF-E2-RELATED FACTOR 2; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878187382     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2476     Document Type: Article

References (36)

1. Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med 359: 492-507, 2008.
2. Sullivan PR: Brain tumors. N Engl J Med 344: 1478; author reply 1479, 2001.
3. Chen J, McKay RM and Parada LF: Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell 149: 36-47, 2012.
4. Lau A, Villeneuve NF, Sun Z, Wong PK and Zhang DD: Dual roles of Nrf2 in cancer. Pharmacol Res 58: 262-270, 2008.
5. Dinkova-Kostova AT, Liby KT, Stephenson KK, et al: Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA 102: 4584-4589, 2005. (Pubitemid 40397155)
6. Kwak MK, Itoh K, Yamamoto M, Sutter TR and Kensler TW: Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3- thione. Mol Med 7: 135-145, 2001. (Pubitemid 33702029)
7. Shih AY, Li P and Murphy TH: A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. J Neurosci 25: 10321-10335, 2005. (Pubitemid 41636229)
8. Yan W, Wang HD, Feng XM, Ding YS, Jin W and Tang K: The expression of NF-E2-related factor 2 in the rat brain after traumatic brain injury. J Trauma 66: 1431-1435, 2009.
9. Wang J, Fields J, Zhao C, et al: Role of Nrf2 in protection against intracerebral hemorrhage injury in mice. Free Radic Biol Med 43: 408-414, 2007. (Pubitemid 46977628)
10. Hayes JD and McMahon M: NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34: 176-188, 2009.
11. Hayes JD and McMahon M: The double-edged sword of Nrf2: subversion of redox homeostasis during the evolution of cancer. Mol Cell 21: 732-734, 2006. (Pubitemid 43376123)
12. Kensler TW and Wakabayashi N: Nrf2: friend or foe for chemoprevention? Carcinogenesis 31: 90-99, 2010.
13. Homma S, Ishii Y, Morishima Y, et al: Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 15: 3423-3432, 2009.
14. Yamadori T, Ishii Y, Homma S, et al: Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene 45: 4768-4777, 2012.
15. Lister A, Nedjadi T, Kitteringham NR, et al: Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer 10: 37, 2011.
16. Kim TH, Hur EG, Kang SJ, et al: NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Cancer Res 71: 2260-2275, 2011.
17. Pan H, Wang H, Zhu L, Mao L, Qiao L and Su X: The role of Nrf2 in migration and invasion of human glioma cell U251. World Neurosurg: Nov 7, 2011 (Epub ahead of print).
18. Rousseau A, Mokhtari K and Duyckaerts C: The 2007 WHO classification of tumors of the central nervous system - what has changed? Curr Opin Neurol 21: 720-727, 2008.
19. Bustin SA, Benes V, Garson JA, et al: The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622, 2009.
20. Hu Z, Lin D, Yuan J, et al: Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11: 4646-4652, 2005. (Pubitemid 41557181)
21. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
22. Wang M, Tang J, Liu S, Yoshida D and Teramoto A: Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas. J Neurooncol 71: 3-7, 2005. (Pubitemid 40277246)
23. Yerushalmi R, Woods R, Ravdin PM, Hayes MM and Gelmon KA: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174-183, 2010.
24. Moi P, Chan K, Asunis I, Cao A and Kan YW: Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA 91: 9926-9930, 1994. (Pubitemid 24311921)
25. Padmanabhan B, Tong KI, Ohta T, et al: Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 21: 689-700, 2006. (Pubitemid 43290735)
26. Singh A, Misra V, Thimmulappa RK, et al: Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 3: e420, 2006.
27. Shibata T, Kokubu A, Gotoh M, et al: Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135: 1358-1368, 2008.
28. Nioi P and Nguyen T: A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun 362: 816-821, 2007. (Pubitemid 47390646)
29. Shibata T, Ohta T, Tong KI, et al: Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 105: 13568-13573, 2008.
30. Konstantinopoulos PA, Spentzos D, Fountzilas E, et al: Keap1 mutations and nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 71: 5081-5089, 2011.
31. Merikallio H, Paakko P, Kinnula VL, Harju T and Soini Y: Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Hum Pathol 43: 577-584, 2011.
32. Singh A, Boldin-Adamsky S, Thimmulappa RK, et al: RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 68: 7975-7984, 2008.
33. Wiesner FG, Magener A, Fasching PA, et al: Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast 18: 135-141, 2009.
34. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995.
35. Niture SK and Jaiswal AK: Nrf2 up-regulates anti-apoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem 287: 9873-9886, 2012.
36. Choi YK, Kim CK, Lee H, et al: Carbon monoxide promotes VEGF expression by increasing HIF-1α protein level via two distinct mechanisms, translational activation and stabilization of HIF-1α protein. J Biol Chem 285: 32116-32125, 2010.